Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc

Legal & General Group Plc increased its position in shares of Pharvaris (NASDAQ:PHVS) by 11.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,855 shares of the company’s stock after purchasing an additional 994 shares during the period. Legal & General Group Plc’s holdings in Pharvaris were worth $189,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in Pharvaris by 3.6% during the fourth quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after buying an additional 189,714 shares in the last quarter. State Street Corp acquired a new stake in shares of Pharvaris during the 3rd quarter valued at $1,000,000. Geode Capital Management LLC boosted its stake in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after acquiring an additional 1,356 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Pharvaris in the 3rd quarter worth $526,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Pharvaris during the fourth quarter worth $196,000.

Pharvaris Trading Down 3.4 %

Shares of NASDAQ PHVS opened at $17.85 on Friday. Pharvaris has a one year low of $11.51 and a one year high of $25.50. The business has a 50-day moving average price of $15.04 and a two-hundred day moving average price of $18.06. The firm has a market capitalization of $933.38 million, a PE ratio of -6.38 and a beta of -2.84.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Monday, April 7th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.06. Research analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

PHVS has been the topic of a number of analyst reports. Cantor Fitzgerald assumed coverage on Pharvaris in a research note on Tuesday. They issued an “overweight” rating and a $28.00 price target on the stock. JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.